Pharmaceuticals
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...
2023-05-09 22:07
3376
PharmAbcine to participate in "BIO International Convention 2023"
DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023. Details...
2023-05-08 20:00
3378
Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China
HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United ...
2023-05-08 19:30
2149
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) diseases, announced today the signing of an exclusive, worldwide...
2023-05-08 14:00
2191
BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701
HANGZHOU, China, May 7, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with option for strategic coll...
2023-05-08 07:00
2638
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE
* Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST * QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in theINVICTUS Phase 3 Study1,2 ...
2023-05-08 04:00
2490
Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted
SUZHOU, China, May 6, 2023 /PRNewswire/ -- Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA. GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne muscular...
2023-05-06 21:00
5191
Empowering Innovation to the Global Market with Acro Certify
NEWARK, Del., May 5, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. These obstacles can come in various forms. Sometimes the problem is finding the right target customer base or establishing an appropriate quality management system and shipping logist...
2023-05-06 10:18
5513
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche'...
2023-05-05 20:50
4091
ProQure and Identiv Partner to Launch Innovative NFC Type 2 Tags for Large-Scale NFC Deployments
The partnership's new PQ201/201s series tags deliver premium features at a competitive price point PLEASANTON, Calif., May 5, 2023 /PRNewswire/ -- ProQure, a technology provider of IoT cloud management for physical objects, and Identiv, a global leader in physical security and secure identificat...
2023-05-05 18:00
3008
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
TAIPEI, May 4, 2023 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the pot...
2023-05-05 08:00
2711
Recall Notice - SD Biosensor, Inc. requests discontinuation of use and disposal of specific Pilot™ COVID-19 At-Home Tests in the United States due to microbial contamination in the liquid buffer solution
SEOUL, South Korea, May 4, 2023 /PRNewswire/ -- SD Biosensor, Inc. today is requesting that consumers stop using and dispose of specific Pilot COVID-19 At-Home Tests inthe United States because potentially harmful bacteria were found in the tube with liquid inside (pouch 2 of the kits). The affe...
2023-05-05 04:00
2847
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ -- ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient wa...
2023-05-05 01:00
3060
Hasten Biopharma Acquires Commercial Rights in China for Roche's Antibiotic Rocephin®
The acquisition will deliver strong commercial synergy with Hasten's current critical care portfolio SHANGHAI, May 4, 2023 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights inChina for Rocephin®, a long-acting, broad spe...
2023-05-04 14:00
2856
EDAN Announces Integration with PointClickCare for Better Senior Primary Care
SAN DIEGO, May 3, 2023 /PRNewswire/ -- Edan Instruments, Inc.
2023-05-03 21:56
3615
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting
SHANGHAI, May 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy...
2023-05-03 12:00
2514
China Jo-Jo Drugstores Receives Hangzhou Municipal People's Government Quality Management Excellence Award
HANGZHOU, China, May 2, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that the Co...
2023-05-02 20:30
3980
I-MAB Filed 2022 Annual Report on Form 20-F
GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20...
2023-05-01 20:00
2641
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CH...
2023-04-29 23:20
4996
IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study
SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants. IMG-004 is a potent, non-covalent, reversible, and brain permeable third-generation Br...
2023-04-28 17:00
2158
Week's Top Stories
Most Reposted
Global virtual travel card program launched by Visa and Trip.com to make travel payments simpler and more seamless in Asia Pacific
[Picked up by 331 media titles]
2026-03-11 11:08TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health
[Picked up by 297 media titles]
2026-03-09 21:36
Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
[Picked up by 296 media titles]
2026-03-10 09:00
PDG Targets USD 5 Billion Debt Raise
[Picked up by 295 media titles]
2026-03-11 10:00The Mastercard Collection: Savor the Extraordinary with Mastercard's Asia Gourmet Circle Program
[Picked up by 295 media titles]
2026-03-12 09:00Most Read
Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
2026-03-10 09:00
5853
NYSE Content Update: America250 Chair Rosie Rios Rings Bell to Highlight Partnership
2026-03-09 21:17
5599
